Oramed Pharmaceuticals Inc (ORMP) - Net Assets
Based on the latest financial reports, Oramed Pharmaceuticals Inc (ORMP) has net assets worth $238.28 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($268.85 Million) and total liabilities ($30.57 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Oramed Pharmaceuticals Inc assets under control for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $238.28 Million |
| % of Total Assets | 88.63% |
| Annual Growth Rate | N/A |
| 5-Year Change | 71.43% |
| 10-Year Change | 662.67% |
| Growth Volatility | 198.98 |
Oramed Pharmaceuticals Inc - Net Assets Trend (2005–2025)
This chart illustrates how Oramed Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Check ORMP intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Oramed Pharmaceuticals Inc (2005–2025)
The table below shows the annual net assets of Oramed Pharmaceuticals Inc from 2005 to 2025. For live valuation and market cap data, see market value of Oramed Pharmaceuticals Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $199.74 Million | +37.43% |
| 2024-12-31 | $145.35 Million | -10.77% |
| 2023-12-31 | $162.89 Million | +7.76% |
| 2022-12-31 | $151.16 Million | +29.73% |
| 2021-12-31 | $116.52 Million | +254.38% |
| 2020-12-31 | $32.88 Million | +69.54% |
| 2019-12-31 | $19.39 Million | -37.67% |
| 2018-12-31 | $31.11 Million | +61.72% |
| 2017-12-31 | $19.24 Million | -26.54% |
| 2016-12-31 | $26.19 Million | +5.49% |
| 2015-12-31 | $24.83 Million | +19.41% |
| 2014-12-31 | $20.79 Million | +155.73% |
| 2013-12-31 | $8.13 Million | +115.21% |
| 2012-12-31 | $3.78 Million | +1.45% |
| 2011-12-31 | $3.72 Million | +348.52% |
| 2010-12-31 | $830.27K | -69.77% |
| 2009-12-31 | $2.75 Million | -40.21% |
| 2008-12-31 | $4.59 Million | +795.33% |
| 2007-12-31 | $513.00K | +218.55% |
| 2006-12-31 | $-432.72K | -865.72% |
| 2005-12-31 | $-44.81K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Oramed Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 12336600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $472.00K | 0.24% |
| Other Components | $322.71 Million | 161.56% |
| Total Equity | $199.74 Million | 100.00% |
Oramed Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Oramed Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
THETA GOLD MNS LTD
F:3LM
|
$149.39 Million |
|
Hsing Ta Cement Co Ltd
TW:1109
|
$149.40 Million |
|
Centrum Medyczne ENEL-MED SA
WAR:ENE
|
$149.44 Million |
|
Capital Small Finance Bank Limited
NSE:CAPITALSFB
|
$149.50 Million |
|
Premium Income Corporation
TO:PIC-A
|
$149.36 Million |
|
Ge Shen Corporation Bhd
KLSE:7197
|
$149.33 Million |
|
Fu Yu Property Co Ltd
TWO:4907
|
$149.26 Million |
|
Torrid Holdings Inc
NYSE:CURV
|
$149.25 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Oramed Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 146,265,000 to 199,744,000, a change of 53,479,000 (36.6%).
- Net income of 64,050,000 contributed positively to equity growth.
- Dividend payments of 10,870,000 reduced retained earnings.
- Share repurchases of 4,741,000 reduced equity.
- Other factors increased equity by 5,040,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $64.05 Million | +32.07% |
| Dividends Paid | $10.87 Million | -5.44% |
| Share Repurchases | $4.74 Million | -2.37% |
| Other Changes | $5.04 Million | +2.52% |
| Total Change | $- | 36.56% |
Book Value vs Market Value Analysis
This analysis compares Oramed Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.87x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2003-12-31 | $0.00 | $4.10 | x |
| 2005-12-31 | $-0.01 | $4.10 | x |
| 2006-12-31 | $-0.16 | $4.10 | x |
| 2007-12-31 | $0.15 | $4.10 | x |
| 2008-12-31 | $1.13 | $4.10 | x |
| 2009-12-31 | $0.58 | $4.10 | x |
| 2010-12-31 | $0.17 | $4.10 | x |
| 2011-12-31 | $0.69 | $4.10 | x |
| 2012-12-31 | $0.64 | $4.10 | x |
| 2013-12-31 | $1.13 | $4.10 | x |
| 2014-12-31 | $2.25 | $4.10 | x |
| 2015-12-31 | $2.29 | $4.10 | x |
| 2016-12-31 | $2.07 | $4.10 | x |
| 2017-12-31 | $1.45 | $4.10 | x |
| 2018-12-31 | $2.09 | $4.10 | x |
| 2019-12-31 | $1.11 | $4.10 | x |
| 2020-12-31 | $1.60 | $4.10 | x |
| 2021-12-31 | $4.07 | $4.10 | x |
| 2022-12-31 | $3.89 | $4.10 | x |
| 2023-12-31 | $4.04 | $4.10 | x |
| 2024-12-31 | $3.58 | $4.10 | x |
| 2025-12-31 | $4.71 | $4.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Oramed Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 32.07%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3202.50%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.16x
- Recent ROE (32.07%) is above the historical average (-75.33%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | 0.00% | 0.00% | 0.00x | 0.00x | $-49.00K |
| 2005 | 0.00% | 0.00% | 0.00x | 0.00x | $-41.30K |
| 2006 | 0.00% | 0.00% | 0.00x | 0.00x | $-371.30K |
| 2007 | -630.80% | 0.00% | 0.00x | 3.78x | $-3.29 Million |
| 2008 | -60.29% | 0.00% | 0.00x | 1.20x | $-3.23 Million |
| 2009 | -100.52% | 0.00% | 0.00x | 1.19x | $-3.04 Million |
| 2010 | -358.60% | 0.00% | 0.00x | 1.75x | $-3.06 Million |
| 2011 | -41.92% | -790.86% | 0.05x | 1.16x | $-1.93 Million |
| 2012 | -88.52% | -1815.15% | 0.03x | 1.40x | $-3.72 Million |
| 2013 | -52.05% | 0.00% | 0.00x | 1.07x | $-5.04 Million |
| 2014 | -27.39% | 0.00% | 0.00x | 1.05x | $-7.78 Million |
| 2015 | -29.13% | 0.00% | 0.00x | 1.06x | $-9.71 Million |
| 2016 | -41.86% | -1710.45% | 0.01x | 1.64x | $-13.58 Million |
| 2017 | -54.48% | -426.71% | 0.06x | 2.01x | $-12.40 Million |
| 2018 | -40.91% | -519.68% | 0.05x | 1.52x | $-15.84 Million |
| 2019 | -74.02% | -531.08% | 0.08x | 1.79x | $-16.29 Million |
| 2020 | -35.01% | -424.76% | 0.06x | 1.36x | $-14.80 Million |
| 2021 | -19.21% | -822.72% | 0.02x | 1.11x | $-33.82 Million |
| 2022 | -24.88% | -1397.11% | 0.02x | 1.06x | $-52.95 Million |
| 2023 | 3.37% | 412.31% | 0.01x | 1.35x | $-10.86 Million |
| 2024 | -13.06% | 0.00% | 0.00x | 1.06x | $-33.73 Million |
| 2025 | 32.07% | 3202.50% | 0.01x | 1.16x | $44.08 Million |
Industry Comparison
This section compares Oramed Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $165,729,232
- Average return on equity (ROE) among peers: -122.45%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Oramed Pharmaceuticals Inc (ORMP) | $238.28 Million | 0.00% | 0.13x | $149.38 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $120.41 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $599.00K | -741.40% | 1.42x | $335.61 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-12.35 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $274.41 Million | -38.23% | 0.17x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $59.19 Million | -23.76% | 0.21x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $10.00K | -200.00% | 3.00x | $31.20 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $11.46 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $-40.09 Million | 0.00% | 0.00x | $3.66 Billion |
About Oramed Pharmaceuticals Inc
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for C… Read more